Last $5.50 USD
Change Today -0.06 / -1.08%
Volume 13.4K
CBRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 4:30 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Snapshot

Open
$5.56
Previous Close
$5.56
Day High
$5.60
Day Low
$5.50
52 Week High
03/18/14 - $7.50
52 Week Low
10/14/14 - $5.30
Market Cap
59.2M
Average Volume 10 Days
36.5K
EPS TTM
$0.45
Shares Outstanding
10.8M
EX-Date
--
P/E TM
12.1x
Dividend
$1.00
Dividend Yield
--
Current Stock Chart for COLUMBIA LABORATORIES INC (CBRX)

Related News

No related news articles were found.

columbia laboratories inc (CBRX) Related Businessweek News

No Related Businessweek News Found

columbia laboratories inc (CBRX) Details

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and analytical and consulting services to the pharmaceutical industry. It focuses on the sale of CRINONE, a progesterone gel to its marketing partner. The company has licensed CRINONE to Merck Serono S.A. outside the United States; and has sold the rights to CRINONE to Actavis, Inc. in the United States. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

77 Employees
Last Reported Date: 03/5/14
Founded in 1986

columbia laboratories inc (CBRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Director and Chief Executive Officer of Molec...
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories Inc. Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014

Columbia Laboratories Inc. Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014 . Venue: The Palmer House Hilton, 17 E. Monroe, Chicago, IL 60603, United States.

Columbia Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Year 2014

Columbia Laboratories Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total net revenues were $11,463,000 compared to $7,126,000 a year ago. The increase reflects higher product and service revenues in addition to a one-time benefit from the sale of intellectual property rights and technology for Legatrin P.M., which contributed $2.2 million to revenues. Income from operations was $3,512,000 compared to $1,267,000 a year ago. Income before income taxes was $3,560,000 compared to $1,721,000 a year ago. Net income was $3,670,000 or $0.34 per diluted share compared to $1,718,000 or $0.11 per diluted share a year ago. Adjusted EBITDA was $4,488,000 compared to $2,484,000 a year ago. Cash flow from operations generated during the three month period ended September 30, 2014 was $5.1 million. For the nine months, the company's total net revenues were $25,568,000 compared to $21,419,000 a year ago. Income from operations was $3,918,000 compared to $5,108,000 a year ago. Income before income taxes was $4,360,000 compared to $5,625,000 a year ago. Net income was $4,292,000 or $0.34 per diluted share compared to $5,617,000 or $0.46 per diluted share a year ago. Adjusted EBITDA was $6,267,000 compared to $7,833,000 a year ago. Including the $2.2 million contribution from the Legatrin P.M. sale, the company now expects full year 2014 revenue growth of 14% to 16%.

Columbia Laboratories Inc., Q3 2014 Earnings Call, Oct 28, 2014

Columbia Laboratories Inc., Q3 2014 Earnings Call, Oct 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $5.50 USD -0.06

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.37 USD +0.32
View Industry Companies
 

Industry Analysis

CBRX

Industry Average

Valuation CBRX Industry Range
Price/Earnings 12.0x
Price/Sales 1.8x
Price/Book 1.4x
Price/Cash Flow 11.1x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit www.columbialabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.